Single Photon Emission Computed Tomography Market By Product Type (Portable, Standalone, and Others), By Type of Radioisotopes (Tc-99m, Ga-67, I-123, Ra-223, Th-201, and Others), By Application (Oncology, Cardiology, Neurology, and Others), By End User (Hospitals, Diagnostic Imaging Centers, and Others), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2025-2034

Report Overview

The Single Photon Emission Computed Tomography Market size is expected to be worth around US$ 6.1 billion by 2034 from US$ 3.2 billion in 2024, growing at a CAGR of 6.6% during the forecast period 2025 to 2034.

Increasing demand for advanced imaging technologies to diagnose and monitor a wide range of medical conditions is driving the growth of the single photon emission computed tomography (SPECT) market. SPECT plays a critical role in evaluating metabolic and functional processes in various organs, making it essential in applications such as cardiac imaging, oncology, and neurology.

The growing prevalence of heart disease, cancer, and neurological disorders contributes to the increasing need for precise diagnostic tools, driving market demand. In May 2024, Cancer Centre London unveiled a cutting-edge SPECT/CT imaging system developed by ICON and Nuttified Health. This advanced system combines the benefits of SPECT and CT to provide superior imaging capabilities, enhancing cancer diagnosis and treatment strategies.

Recent trends highlight significant technological advancements in SPECT systems, including improved resolution and faster imaging times, which increase diagnostic accuracy and patient comfort. Additionally, the integration of artificial intelligence (AI) in SPECT imaging is opening new opportunities for more accurate interpretations of complex medical data. The growing adoption of hybrid imaging systems, like SPECT/CT, reflects a broader shift toward comprehensive, multimodal diagnostic solutions. As the healthcare industry continues to prioritize early detection and personalized treatments, the SPECT market is poised for sustained growth and innovation.

Key Takeaways

• In 2023, the market for Single Photon Emission Computed Tomography generated a revenue of US$ 3.2 billion, with a CAGR of 6.6%, and is expected to reach US$ 6.1 billion by the year 2033.
• The product type segment is divided into portable, standalone, and others, with portable taking the lead in 2023 with a market share of 47.6%.
• Considering type of radioisotopes, the market is divided into Tc-99m, Ga-67, I-123, Ra-223, Th-201, and others. Among these, Ga-67 held a significant share of 32.4%.
• Furthermore, concerning the application segment, the market is segregated into oncology, cardiology, neurology, and others. The oncology sector stands out as the dominant player, holding the largest revenue share of 49.3% in the Single Photon Emission Computed Tomography market.
• The end user segment is segregated into hospitals, diagnostic imaging centers, and others, with the hospitals segment leading the market, holding a revenue share of 54.8%.
• North America led the market by securing a market share of 41.2% in 2023.

Product Type Analysis

The portable segment led in 2023, claiming a market share of 47.6% owing to the increasing demand for flexible, on-the-go diagnostic imaging solutions. Portable SPECT systems provide significant advantages in terms of mobility, making them ideal for use in remote or underserved areas and in situations where space and infrastructure are limited.

The growth of this segment is anticipated to be driven by technological advancements, such as miniaturization and improved imaging capabilities, as well as the need for rapid, efficient diagnostic tools. Furthermore, as healthcare providers aim to enhance patient care and improve accessibility, the demand for portable imaging systems is projected to rise significantly in the coming years.

Type of Radioisotopes Analysis

The Ga-67 held a significant share of 32.4% due to its established role in imaging specific types of cancer, particularly lymphoma and tumors of the head and neck. Ga-67 is an essential radioisotope for detecting and monitoring certain cancers, as well as for evaluating inflammatory conditions.

The segment’s growth is expected to be driven by the continued advancements in radiopharmaceuticals and the increasing adoption of SPECT imaging for cancer diagnosis and treatment planning. The use of Ga-67 in oncology, particularly in cancer staging, is projected to rise as physicians and healthcare providers increasingly rely on precise diagnostic tools for accurate tumor identification.

Application Analysis

The oncology segment had a tremendous growth rate, with a revenue share of 49.3% owing to the increasing prevalence of cancer worldwide and the rising demand for advanced diagnostic imaging techniques. SPECT imaging is a critical tool in oncology for detecting and evaluating cancerous growths, monitoring treatment effectiveness, and assessing metastasis.

The segment’s growth is expected to be driven by the advancement of imaging technologies and radiotracers, as well as a growing emphasis on early cancer detection. As healthcare providers aim for better outcomes and personalized treatment plans, the need for SPECT imaging in oncology is projected to increase, particularly in cancer screening, treatment planning, and monitoring.

End-User Analysis

The hospitals segment grew at a substantial rate, generating a revenue portion of 54.8% as hospitals remain the primary end-users of diagnostic imaging systems. Hospitals have the infrastructure and resources to support advanced imaging technologies like SPECT, and they play a key role in cancer detection, cardiovascular health monitoring, and neurological assessments.

The segment’s growth is anticipated to be supported by increasing healthcare investments, a rising focus on early detection of diseases, and the growing importance of personalized medicine. With the rise in chronic diseases and cancer rates, hospitals are expected to expand their use of SPECT technology for both diagnosis and treatment monitoring, thus driving growth in this segment.

Key Market Segments

By Product Type

• Portable
• Standalone
• Others

By Type of Radioisotopes

• Tc-99m
• Ga-67
• I-123
• Ra-223
• Th-201
• Others

By Application

• Oncology
• Cardiology
• Neurology
• Others

By End User

• Hospitals
• Diagnostic Imaging Centers
• Others

Drivers

Growing Prevalence of Cancer Driving the Single Photon Emission Computed Tomography Market

Growing prevalence of cancer is anticipated to drive the single photon emission computed tomography (SPECT) market significantly. The International Agency for Research on Cancer (IARC) projected in 2022 that global cancer diagnoses could reach 27.5 million by 2040, reflecting a 70% surge in the worldwide cancer burden over the next two decades. SPECT imaging plays a crucial role in cancer detection and monitoring by providing detailed insights into tumor metabolism and physiology.

Oncologists increasingly rely on SPECT scans to evaluate the effectiveness of treatments and make informed decisions about patient care. Advances in radiotracers enhance the precision of imaging, enabling better localization of cancerous tissues. Hospitals and diagnostic centers adopt state-of-the-art SPECT systems to meet the growing demand for early and accurate cancer diagnosis.

Portable and hybrid SPECT/CT technologies expand accessibility in both urban and remote healthcare settings. Collaborative research initiatives foster the development of next-generation SPECT solutions tailored to oncology applications. These trends highlight the critical role of SPECT imaging in addressing the rising prevalence of cancer globally.

Restraints

High Costs Are Restraining the Single Photon Emission Computed Tomography Market

High costs associated with single photon emission computed tomography systems are restraining the market. Advanced SPECT systems, particularly hybrid models with integrated CT functionality, require substantial investment in development and manufacturing. Smaller diagnostic centers and hospitals face financial constraints in acquiring these high-cost devices.

Operational expenses, including maintenance, software updates, and radiopharmaceuticals, further add to the financial burden. Limited reimbursement policies for SPECT imaging procedures discourage adoption in cost-sensitive regions. Training medical personnel to operate complex systems increases operational costs for healthcare providers. In developing countries, inadequate infrastructure and funding limit access to advanced diagnostic imaging. Addressing these barriers requires cost-effective innovations and supportive reimbursement frameworks to improve affordability and accessibility.

Opportunities

Increasing Innovation as an Opportunity for the Single Photon Emission Computed Tomography Market

Increasing innovation is anticipated to create significant opportunities for the single photon emission computed tomography market. In October 2022, Spectrum Dynamics introduced its VERITON-CT-400 Series, an advanced digital scanner equipped with solid-state detectors and a wide bore for imaging high-energy isotopes. These innovations enhance image resolution and scanning efficiency, meeting the growing demand for precision diagnostics.

Technological advancements improve system sensitivity, enabling early detection of diseases like cancer and cardiovascular conditions. Portable and compact designs cater to smaller healthcare facilities, expanding market penetration. Collaboration between research organizations and medical device manufacturers accelerates the development of cutting-edge SPECT solutions.

Integration of artificial intelligence in image processing enhances diagnostic accuracy, optimizing clinical workflows. Expanding government support for nuclear medicine research boosts innovation and adoption of advanced imaging systems. These trends underscore the transformative potential of innovation in advancing the SPECT market and improving patient outcomes.

Impact of Macroeconomic / Geopolitical Factors

Macroeconomic and geopolitical factors significantly shape the single photon emission computed tomography (SPECT) market. On the positive side, increasing global healthcare investments and a growing demand for advanced diagnostic tools drive the adoption of SPECT systems. As the prevalence of chronic diseases such as cardiovascular conditions and cancer rises, the need for accurate, non-invasive imaging solutions expands, boosting market growth.

However, economic downturns or healthcare budget cuts may restrict access to high-cost imaging technologies, limiting their adoption, particularly in low-income regions. Geopolitical tensions, such as trade barriers, regulatory discrepancies, and political instability, may disrupt supply chains for essential components, leading to increased costs and production delays.

Moreover, fluctuating healthcare policies and reimbursement rates in different countries could affect the affordability and accessibility of SPECT systems. Despite these challenges, the growing focus on early detection, precision medicine, and non-invasive diagnostic techniques ensures continued demand and a positive outlook for the market’s future growth.

Latest Trends

Rise in Mergers and Acquisitions Driving the Single Photon Emission Computed Tomography Market

Rising mergers and acquisitions are driving significant growth in the single photon emission computed tomography (SPECT) market. High levels of consolidation among medical device manufacturers and imaging technology companies are expected to enhance the development and distribution of more advanced and cost-effective SPECT systems.

These strategic alliances enable firms to leverage each other’s strengths, such as advanced technology and manufacturing capabilities, to bring innovative solutions to the market. Increasing demand for advanced imaging technologies in oncology, cardiology, and neurology is likely to stimulate further market growth.

In May 2022, Mediso Ltd, a key player in the SPECT industry, revealed plans to acquire Bartec Technologies Ltd. Bartec, a UK-based company, specializes in the supply and installation of molecular imaging systems and related accessories. As more mergers and acquisitions occur, the market is anticipated to experience enhanced technological development and greater accessibility to SPECT imaging solutions, contributing to its long-term growth.

Regional Analysis

North America is leading the Single Photon Emission Computed Tomography Market

North America dominated the market with the highest revenue share of 41.2% owing to the rising prevalence of chronic diseases and advancements in imaging technology. According to the American Cancer Society, an estimated 1.9 million people were diagnosed with cancer in the United States in 2022, highlighting the growing demand for effective diagnostic tools like SPECT.

The increasing focus on early detection of cancer, cardiovascular conditions, and neurological disorders fueled the adoption of advanced imaging systems. Integration of artificial intelligence into SPECT technology improved image quality and diagnostic accuracy, further driving its usage. Government funding for research initiatives and the presence of established healthcare infrastructure strengthened market growth.

Collaborations between academic institutions and manufacturers enabled technological advancements, expanding the scope of SPECT applications. Rising awareness about nuclear medicine among healthcare providers and patients contributed to increased demand for this technology. Additionally, the availability of hybrid systems, combining SPECT with CT or MRI, enhanced diagnostic capabilities, attracting more healthcare facilities to adopt these solutions.

The Asia Pacific region is expected to experience the highest CAGR during the forecast period

Asia Pacific is expected to grow with the fastest CAGR owing to increasing investments in healthcare infrastructure and rising disease burdens. Expanding healthcare access in countries like India, China, and Japan is likely to support the adoption of advanced diagnostic tools. The rising incidence of cardiovascular and neurological conditions in the region is projected to drive demand for precise imaging techniques.

Government initiatives promoting nuclear medicine and radiopharmaceutical production are expected to lower costs and improve accessibility. Growing collaborations between local manufacturers and global players are anticipated to introduce cost-effective and innovative SPECT solutions. Academic institutions in the region are likely to expand their research programs, boosting the adoption of imaging systems for clinical studies.

Increasing medical tourism, supported by affordable diagnostic services, is estimated to further strengthen the market. The growing geriatric population in Asia Pacific is likely to contribute to the demand for advanced imaging for age-related diseases. Continuous technological advancements in hybrid imaging systems are expected to enhance diagnostic efficiency and attract significant adoption.

Key Regions and Countries

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Russia
  • Netherland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Australia
  • New Zealand
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of MEA

Key Players Analysis

Key players in the single photon emission computed tomography (SPECT) market focus on developing hybrid imaging systems, such as SPECT/CT, to enhance diagnostic accuracy by combining functional and anatomical imaging. Companies invest in research to improve image resolution and reduce scan time, addressing the needs of oncology, cardiology, and neurology applications.

Strategic collaborations with healthcare providers and research institutions help drive adoption and expand clinical utility. Geographic expansion into regions with rising demand for advanced diagnostic tools supports market growth. Many players also integrate artificial intelligence to streamline workflows and enhance diagnostic interpretation.

GE Healthcare is a leading company in this market, offering state-of-the-art SPECT systems like the Discovery NM/CT series. The company emphasizes innovation by integrating advanced detectors and hybrid imaging capabilities, enabling accurate and efficient diagnostics. GE Healthcare’s global presence and strong focus on technological advancements establish it as a prominent player in the molecular imaging industry.

Recent Developments

• In June 2022, Siemens Healthineers received FDA clearance for its cutting-edge Symbia Pro. Specta scanner. This system integrates advanced SPECT/CT technology, enabling low-dose CT imaging with up to 64 slices for better accuracy and safety.
• In June 2024, the QEII Health Sciences Centre in Halifax, Nova Scotia, became Canada’s first medical facility to implement the Starguide hybrid SPECT/CT scanner. This innovative technology merges SPECT and CT imaging to deliver exceptionally accurate and detailed scans, enhancing diagnostic precision.

Top Key Players in the Single Photon Emission Computed Tomography Market

• Spectrum Dynamics Medical
• Siemens Healthineers
• QEII Health Sciences Centre
• MILabs B.V.
• Mediso Medical Imaging Systems
• Koninklijke Philips
• GE Healthcare
• Digirad Corporation

Report Scope